

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to:
www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	11
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	24
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	38
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	41
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	44
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

Canada (Canada and United States)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	1	1.30	1.70
Year of IDU prevalence estimate	2004		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	2.9	13.4	23.8
Year of HIV prevalence among IDU estimate	2005		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	23 154 622 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	231 500	301 000	393 500
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	6714	40 334	93 653

1. Needle and syringe programs (NSPs)

NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other NSP indicators
When were NSPs first introduced?	1989
Reference	Canadian HIV/AIDS Legal Network (2005). Info Sheets on Injection Drug Use and HIV/AIDS. Toronto, Canadian HIV/AIDS Legal Network. Sendziuk, P. (2007). "Harm reduction and HIV-prevention among injecting drug users in Australia: an international comparison." Canadian Bulletin of Medical History/Bulletin Canadien d'Histoire de la Medecine 24(1): 113-29.
Are needles and syringes available for purchase from pharmacies?	Yes
Most recent year of documentation	2008
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.

NSP 2: Number of NSP sites

Data reported	Almost 200 syringe exchanges in BC 63% of 913 services provides needles and syringes for free in Quebec		
Year of reported data	2009		
Reference	Buxton, J. Personal Communication: Response to "Canada - UN Reference Group - Final Data Check". Canada, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 24 Sep 2009. National Institute of Public Health Ministry of Health and Human Services Quebec Canada (2009). Official list of centers access to injection equipment Quebec (distribution and sales).		
Adjustments	- Calculated the number of sites in Quebec		
Final/Adjusted data (to be used as indicator numerator)	775 (SN)		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	12 268 591 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	122 500	159 500	208 500
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	3.72	4.86	6.33

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported	Needles and syringes available for purchase from pharmacies but number of sites not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	2004		
General population 15-64 years of age at year of reported data	23 154 622 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	231 500	301 000	393 500
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data	(source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	NSP present but number not known		
Year of reported data	2005		
Reference	Canadian HIV/AIDS Legal Network (2005). Info Sheets on Injection Drug Use and HIV/AIDS. Toronto, Canadian HIV/AIDS Legal Network. Ogborne, A., V. Carver, et al. (2005). Harm reduction and drug use: an international comparative study of contextual factors influencing the development and implementation of relevant policies and programs, Canadian Centre for Substance Abuse (CCSA).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 378 740 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	224 000	291 000	380 500
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	NK	NK	NK

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	10 5086 occasions of services in Quebec from April 2007 to Mar 2008		
Year of reported data	2008		
Reference	National Institute of Public Health Ministry of Health and Human Services Quebec Canada (2009). Official list of centers access to injection equipment Quebec (distribution and sales).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	105 086		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	7 750 500 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	101 000	132 000
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	0.80	1.04	1.36

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	5 023 600 syringes ordered for distribution in British Columbia from April 1 2006 to Feb 15 2007 1 522 999 syringes distributed in Quebec from April 07 to Mar 08		
Year of reported data	2008		
Reference	Buxton, J., A. Mehrabadi, et al. (2007). Vancouver drug use epidemiology, Canadian Community Epidemiology Network on Drug Use (CCENDU),. National Institute of Public Health Ministry of Health and Human Services Quebec Canada (2009). Official list of centers access to injection equipment Quebec (distribution and sales).		
Adjustments	Figures taken as range and assumed rate of distribution is the same in 2008 for BC Assumed syringes ordered for distribution in British Columbia was equal to number of syringes distributed and assumed rate of distribution over 12 month period is constant and adjusted 10.5 month figure accordingly		
Final/Adjusted data (to be used as indicator numerator)	7 264 256 (SN)		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	12 132 100 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	121 500	157 500	206 000
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	35.26	46.1	59.79

NSP: All documents reviewed

- Buxton, J. Personal Communication: Response to "Canada - UN Reference Group - Final Data Check". Canada, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 24 Sep 2009.
- Buxton, J., A. Mehrabadi, et al. (2007). Vancouver drug use epidemiology, Canadian Community Epidemiology Network on Drug Use (CCENDU), Canadian Centre on Substance Abuse (2006). Fact Sheet: Crack Cocaine. Ottawa, CCSA.
- Canadian HIV/AIDS Legal Network (2005). Info Sheets on Injection Drug Use and HIV/AIDS. Toronto, Canadian HIV/AIDS Legal Network.
- CBC News (2009). Needle-exchange program curbing disease: Sask. study. Province wants to improve cleanup of used needles. Toronto, Ontario.
- CBC News. (2008). "Wait list for N.B. drug treatment shrinks, needle-exchange numbers rise." Retrieved 3 April, 2009, from <http://www.cbc.ca/canada/new-brunswick/story/2008/01/23/methadone-treatment.html>.
- Dias, G. and G. Betteridge (2007). Hard Time: HIV and Hepatitis C Prevention Programming for Prisoners in Canada. . Toronto, Canadian HIV/AIDS Legal Network and Prisoners' HIV/AIDS Support Action Network.
- Dolan, K., M. MacDonald, et al. (2005). Needle and Syringe Programs: A Review of the Evidence. Canberra, Australian Government Department of Health and Ageing,.
- Drucker, E. (2006). "Insite: Canada's landmark safe injecting program at risk." *Harm Reduction Journal* 3(1): 24.
- Expert Advisory Committee to the Federal Health Minister Canada (2008). Vancouver's INSITE Service and Other Supervised Injection Sites: What Has Been Learned from Research? Final Report of the Expert Advisory Committee on Supervised Injection Site Research. Ottawa, Health Canada.
- Fast, D., W. Small, et al. (2008). "The perspectives of injection drug users regarding safer injecting education delivered through a supervised injecting facility." *Harm Reduction Journal* 5(1): 32.
- Hogg, R., S. Strathdee, et al. (2005). "HIV Prevalence among Aboriginal British Columbians." *Harm Reduction Journal* 2(1): 26.
- International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.
- Islam, M. M. and K. Conigrave (2007). "Assessing the role of syringe dispensing machines and mobile van outlets in reaching hard-to-reach and high-risk groups of injecting drug users (IDUs): a review." *Harm Reduction Journal* 4(1): 14.
- Kerr, T., J. Kimber, et al. (2007). "The role of safer injection facilities in the response to HIV/AIDS among injection drug users." *Current HIV/AIDS Reports* 4(4): 158-64.
- Kuyper, L. M., T. Kerr, et al. (2006). "Factors associated with buying and selling syringes among injection drug users in a setting of one of North America's largest syringe exchange programs." *Substance Use & Misuse* 41(6-7): 883-99.
- Leonard, L., E. DeRubeis, et al. (2008). "'I inject less as I have easier access to pipes': injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed." *International Journal of Drug Policy* 19(3): 255-64.
- Moore, G., P. McCarthy, et al. (2004). A review of harm reduction approaches in Ireland and evidence from the international literature. Dublin, National Advisory Committee on Drugs.
- Morissette, C., J. Cox, et al. (2007). "Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention." *International Journal of Drug Policy* 18(3): 204-12.
- National Institute of Public Health Ministry of Health and Human Services Quebec Canada (2009). Official list of centers access to injection equipment Quebec (distribution and sales).
- Ogborne, A., V. Carver, et al. (2005). Harm reduction and drug use: an international comparative study of contextual factors influencing the development and implementation of relevant policies and programs, Canadian Centre for Substance Abuse (CCSA).
- Open Society Institute (2007). "News report shows benefit of Prison Needle Exchange." Retrieved 1st December, 2008, from http://www.soros.org/initiatives/health/focus/ihrd/news/prisonnep_20041027.
- Rupert, J. (2009). Drug users turn in 99% of needles. *Ottawa Citizen*. Ottawa, Ontario.
- Sendziuk, P. (2007). "Harm reduction and HIV-prevention among injecting drug users in Australia: an international comparison." *Canadian Bulletin of Medical History/Bulletin Canadien d'Histoire de la Medecine* 24(1): 113-29.
- Small, W., E. Wood, et al. (2008). "Decline in needle exchange use in Vancouver, Canada coincides with the Australian heroin shortage.[comment]." *International Journal of Drug Policy* 19(4): 291-2; discussion 295-6.
- Strike, C., K. Leonard, et al. (2006). Ontario needle exchange programs: Best practice recommendations. Ontario Needle Exchange Coordinating Committee. Toronto.
- Strike, C., Leonard, L., Millson, M, Anstice, S, Berkeley, N, & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.

NSP: All documents reviewed

The Macfarlane Burnet Institute for Medical Research & Public Health Ltd (2005). Policy and programming guide for HIV/AIDS prevention and care among injecting drug users. Melbourne, World Health Organisation: department of HIV/AIDS.

Thomas, G. (2005). Assessing the need for prison-based needle exchange programs in Canada: a situational analysis: 20.

Tyndall, M. W., M. McNally, et al. (2007). "Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes." *International Journal of Drug Policy* 18(4): 281-7.

Tyndall, M. W., T. Kerr, et al. (2006). "Attendance, drug use patterns, and referrals made from North America's first supervised injection facility." *Drug & Alcohol Dependence* 83(3): 193-8.

Wood, E., M. Tyndall, et al. (2006). Service Uptake and Characteristics of Injection Drug Users Utilizing North America's First Medically Supervised Safer Injecting Facility, *Am Public Health Assoc.* 96: 770-773.

Wood, E., M. W. Tyndall, et al. (2006). "Attendance at supervised injecting facilities and use of detoxification services." *New England Journal of Medicine* 354(23): 2512-4.

2. Opioid substitution treatment (OST)**OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other OST indicators
When was agonist OST first available?	
Reference	

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	Yes
Comments	
Most recent year of documentation	2007
Reference	See references for other OST indicators
When was MMT first available?	
Reference	

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	Yes
Comments	
Most recent year of documentation	2005
Reference	Strike, C., Leonard, L., Millson, M., Anstice, S., Berkeley, N., & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.
When was BMT first available?	2005
Reference	Strike, C., Leonard, L., Millson, M., Anstice, S., Berkeley, N., & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	
Comments	
Most recent year of documentation	
Reference	
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	75-80 mg
Comments	Average daily dose of MMT
Year	2004
Reference	Kerr, T., D. Marsh, et al. (2005). "Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver." <i>Drug & Alcohol Dependence</i> 80(3): 329-35.
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	OST available but number of sites not known		
Year of reported data	2004		
Reference	Kerr, T., D. Marsh, et al. (2005). "Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver." <i>Drug & Alcohol Dependence</i> 80(3): 329-35.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 097 129 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	221 000	287 500	375 500
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 8: Number of sites providing MMT

Data reported	MMT available but number of sites not known		
Year of reported data	2004		
Reference	Kerr, T., D. Marsh, et al. (2005). "Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver." <i>Drug & Alcohol Dependence</i> 80(3): 329-35.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 097 129 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	221 000	287 500	375 500
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 9: Number of sites providing BMT

Data reported	BMT available but number not known		
Year of reported data	2005		
Reference	Strike, C., Leonard, L, Millson, M, Anstice, S, Berkeley, N, & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 378 740 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	224 000	291 000	380 500
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

OST 11: Number of all clients in any OST at a single point in time

Data reported	OST available but number of clients on OST not known		
Year of reported data	2004		
Reference	Kerr, T., D. Marsh, et al. (2005). "Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver." <i>Drug & Alcohol Dependence</i> 80(3): 329-35.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 097 129 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	221 000	287 500	375 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 12: Number of all clients in MMT at a single point in time

Data reported	MMT available but number of clients not known		
Year of reported data	2004		
Reference	Kerr, T., D. Marsh, et al. (2005). "Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver." <i>Drug & Alcohol Dependence</i> 80(3): 329-35.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 097 129 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	221 000	287 500	375 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 13: Number of all clients in BMT at a single point in time

Data reported	BMT available but number of clients not known		
Year of reported data	2005		
Reference	Strike, C., Leonard, L, Millson, M, Anstice, S, Berkeley, N, & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 378 740 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	224 000	291 000	380 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2004		
Reference	Kerr, T., D. Marsh, et al. (2005). "Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver." <i>Drug & Alcohol Dependence</i> 80(3): 329-35.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 097 129 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	221 000	287 500	375 500
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2006		
Reference	Buxton, J., A. Mehrabadi, et al. (2007). Vancouver drug use epidemiology, Canadian Community Epidemiology Network on Drug Use (CCENDU),.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 650 169 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	226 500	294 500	385 000
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2005		
Reference	Strike, C., Leonard, L, Millson, M, Anstice, S, Berkeley, N, & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 378 740 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	224 000	291 000	380 500
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	7856 clients received MMT in 7.5 months period in British Columbia BMT available but number not known		
Year of reported data	2006		
Reference	Buxton, J., A. Mehrabadi, et al. (2007). Vancouver drug use epidemiology, Canadian Community Epidemiology Network on Drug Use (CCENDU),.		
Adjustments	Assumed no additional clients received MMT in 12 month period		
Final/Adjusted data (to be used as indicator numerator)	7856 (SN)		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	4 243 600 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	42 500	55 000	72 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	10.91	14.28	18.48

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	7856 clients received MMT in 7.5 months period in British Columbia		
Year of reported data	2006		
Reference	Buxton, J., A. Mehrabadi, et al. (2007). Vancouver drug use epidemiology, Canadian Community Epidemiology Network on Drug Use (CCENDU),.		
Adjustments	Assumed no additional clients received MMT in 12 month period		
Final/Adjusted data (to be used as indicator numerator)	7856 (SN)		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	4 243 600 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	42 500	55 000	72 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	10.91	14.28	18.48

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	BMT available but number of clients not known		
Year of reported data	2005		
Reference	Strike, C., Leonard, L, Millson, M, Anstice, S, Berkeley, N, & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 378 740 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	224 000	291 000	380 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2004		
Reference	Kerr, T., D. Marsh, et al. (2005). "Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver." <i>Drug & Alcohol Dependence</i> 80(3): 329-35.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 097 129 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	221 000	287 500	375 500
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2006		
Reference	Buxton, J., A. Mehrabadi, et al. (2007). Vancouver drug use epidemiology, Canadian Community Epidemiology Network on Drug Use (CCENDU),.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 650 169 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	226 500	294 500	385 000
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2005		
Reference	Strike, C., Leonard, L, Millson, M, Anstice, S, Berkeley, N, & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 378 740 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	224 000	291 000	380 500
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High

OST: All documents reviewed

(2005). "Across Canada." *Newfoundland National Review of Medicine* 2(1): 1-2.

Canadian Centre on Substance Abuse (2006). *Fact Sheet: Crack Cocaine*. Ottawa, CCSA.

Canadian HIV/AIDS Legal Network (2005). *Info Sheets on Injection Drug Use and HIV/AIDS*. Toronto, Canadian HIV/AIDS Legal Network.

Canadian HIV/AIDS Legal Network (2006). *Prison needle exchange: Lessons from a comprehensive review of international evidence and*

CBC News. (2007). "N.B. Addicts Forced to Go to N.S. for Methadone." Retrieved 7 Nov, 2008, from <http://www.cbc.ca/canada/new-brunswick/story/2007/04/13/nb-nsmethadone.html>

Dias, G. and G. Betteridge (2007). *Hard Time: HIV and Hepatitis C Prevention Programming for Prisoners in Canada*. Toronto, Canadian HIV/AIDS Legal Network and Prisoners' HIV/AIDS Support Action Network.

Dolan, K., E. M. Khoei, et al. (2007). *Prisons and Drugs: A global review of incarceration, drug use and drug services*. The beckley foundation drug policy programme.

Fischer, B., J. Rehm, et al. (2005). "Illicit opioid use in Canada: Comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study)." *Journal of Urban Health* 82(2): 250-266.

Hariri, S. (2008). "New Opioid Addiction Med Hits Canada: Buprenorphine Offers Alternative to Methadone, Reduces OD Risk." *National Review of Medicine* 5(1).

International Harm Reduction Association (IHRA) (2007). *Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland*.

Jurgens, R. (2007). *Interventions to address HIV in prisons: drug dependence treatments. Evidence for action technical papers*. Geneva, World Health Organisation (WHO).

Jurgens, R. and G. Betteridge (2005). "Prisoners who inject drugs: public health and human rights imperatives." *Health & Human Rights* 8(2): 46-

Kerr, T., D. Marsh, et al. (2005). "Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver." *Drug & Alcohol Dependence* 80(3): 329-35.

Ogborne, A., V. Carver, et al. (2005). *Harm reduction and drug use: an international comparative study of contextual factors influencing the development and implementation of relevant policies and programs*, Canadian Centre for Substance Abuse (CCSA).

Strike, C. J., W. Gnam, et al. (2008). "Retention in methadone maintenance treatment: a preliminary analysis of the role of transfers between methadone prescribing physicians." *The Open Addiction Journal* 1: 10-13.

Strike, C., K. Leonard, et al. (2006). *Ontario needle exchange programs: Best practice recommendations*. Ontario Needle Exchange Coordinating Committee. Toronto.

Strike, C., K. Urbanoski, et al. (2005). "Policy Changes and the Methadone Maintenance Treatment System for Opioid Dependence in Ontario, 1996 to 2001." *J Addict Dis* 24(1): 39-51.

Strike, C., Leonard, L., Millson, M., Anstice, S., Berkeley, N., & Medd, E (2006). *Ontario Needle Exchange Programs: Best Practice Recommendations*. Ontario, Ontario Needle Exchange Coordinating Committee: 266.

Thomas, G. (2005). *Assessing the need for prison-based needle exchange programs in Canada: a situational analysis*: 20.

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High

ODT 1.2: Number of IDUs receiving detoxification

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High

ODT 2.3: Number of all clients in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	Yes		
Number of sites - data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2007		
Reference	Wood, E., M. Tyndall, et al. (2006). Service Uptake and Characteristics of Injection Drug Users Utilizing North America's First Medically Supervised Safer Injecting Facility, Am Public Health Assoc. 96: 770-773.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 910 443 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	229 000	298 000	389 500
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychotherapy, counselling or psychosocial support present but number not known		
Year of reported data	2007		
Reference	Wood, E., M. Tyndall, et al. (2006). Service Uptake and Characteristics of Injection Drug Users Utilizing North America's First Medically Supervised Safer Injecting Facility, Am Public Health Assoc. 96: 770-773.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 910 443 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	229 000	298 000	389 500
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychotherapy, counselling or psychosocial support present but number not known		
Year of reported data	2007		
Reference	Wood, E., M. Tyndall, et al. (2006). Service Uptake and Characteristics of Injection Drug Users Utilizing North America's First Medically Supervised Safer Injecting Facility, Am Public Health Assoc. 96: 770-773.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 910 443 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	229 000	298 000	389 500
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	1166 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	1166		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	23 154 622 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	231 500	301 000	393 500
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	2.96	3.87	5.04

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	23 154 622 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	231 500	301 000	393 500
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	23 154 622 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	231 500	301 000	393 500
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High

ODT 6 - Drug treatment in prisons**ODT 6.1: Number of prison drug treatment sites**

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High

ODT: All documents reviewed

Canadian Addiction Survey 2003/2004 Cited in Public Health Agency of Canada (undated). "People who Use Injection Drugs Factsheet." Retrieved 6 Nov, 2008, from http://www.phac-aspc.gc.ca/aids-sida/populations_e.html#pe.

Leonard, L., E. DeRubeis, et al. (2008). "'I inject less as I have easier access to pipes': injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed." *International Journal of Drug Policy* 19(3): 255-64.

Ogborne, A., V. Carver, et al. (2005). Harm reduction and drug use: an international comparative study of contextual factors influencing the development and implementation of relevant policies and programs, Canadian Centre for Substance Abuse (CCSA).

Wood, E., M. Tyndall, et al. (2006). Service Uptake and Characteristics of Injection Drug Users Utilizing North America's First Medically Supervised Safer Injecting Facility, *Am Public Health Assoc.* 96: 770-773.

4. HIV testing and counselling (T&C)**T&C 1: Availability of HIV T&C**

Is T&C available?	Yes
Most recent year of data	2007
Reference	See references for other VCT indicators

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	VCT available but number not known		
Year of reported data	2007		
Reference	UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	22 910 443 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	229 000	298 000	389 500
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	2007
Reference	UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.
Data reported for both male and female IDUs	59% IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	59.00%
Data reported for male IDUs	
Adjustments	
Final/Adjusted data	
Data reported for female IDUs	
Adjustments	
Final/Adjusted data	

T&C: All documents reviewed

Health Canada (2004). I-Track: Enhanced Surveillance of Risk Behaviours among Injecting Drug Users in Canada (Pilot Survey). Ottawa, Health

Strike, C., K. Leonard, et al. (2006). Ontario needle exchange programs: Best practice recommendations. Ontario Needle Exchange Coordinating Committee. Toronto.

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
HIV among IDU prevalence estimate (%)	Low	Mid	High
Reference			
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
HIV among IDU prevalence estimate (%)	Low	Mid	High
Reference			
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	
Year of reported data	
Reference	

ARV: All documents reviewed

Canadian HIV/AIDS Legal Network (2005). Info Sheets on Injection Drug Use and HIV/AIDS. Toronto, Canadian HIV/AIDS Legal Network.

Health Canada (2004). I-Track: Enhanced Surveillance of Risk Behaviours among Injecting Drug Users in Canada (Pilot Survey). Ottawa, Health

Kerr, T., A. Palepu, et al. (2004). "Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver." *Antiviral Therapy* 9(3): 407-14.

Lloyd-Smith, E., E. Brodtkin, et al. (2006). "Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia." *AIDS* 20(3): 445-50.

Public Health Agency of Canada (2006). I-Track: Enhanced surveillance of Risk Behaviours among Injecting Drug Users in Canada.

Rusch, M., S. Nixon, et al. (2004). "Use of antiretroviral therapy among HIV positive individuals living in British Columbia." *AIDS Care* 16(7): 914-

Tyndall, M. W., M. McNally, et al. (2007). "Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes." *International Journal of Drug Policy* 18(4): 281-7.

Vlahov, D. and D. D. Celentano (2006). "Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death.[see comment]." *Cadernos de Saude Publica* 22(4): 705-18.

Wood, E., J. S. G. Montaner, et al. (2004). "Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users." *Antiviral Therapy* 9(2): 229-35.

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	
Year	2005
Reference	See references for other Condom indicators

Condoms 2: Number of sites distributing condoms to IDUs

Data reported	Condoms available from syringe exchange sites 775 NSP sites in British Columbia and Quebec [number of sites in other provinces not known]		
Year of reported data	2009		
Reference	<p>Canadian HIV/AIDS Legal Network (2005). Info Sheets on Injection Drug Use and HIV/AIDS. Toronto, Canadian HIV/AIDS Legal Network.</p> <p>Ogborne, A., V. Carver, et al. (2005). Harm reduction and drug use: an international comparative study of contextual factors influencing the development and implementation of relevant policies and programs, Canadian Centre for Substance Abuse (CCSA)</p> <p>Buxton, J. Personal Communication: Response to "Canada - UN Reference Group - Final Data Check". Canada, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 24 Sep 2009.</p> <p>National Institute of Public Health Ministry of Health and Human Services Quebec Canada (2009). Official list of centers access to injection equipment Quebec (distribution and sales).</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	>775 (SN)		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	12 268 591 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	122 500	159 500	208 500
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	3.72	4.86	6.33

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported	3000000 condoms distributed to IDUs in British Columbia each year [data for other provinces not available]		
Year of reported data	2009		
Reference	Buxton, J. Personal Communication: Response to "Canada - UN Reference Group - Final Data Check". Canada, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 24 Sep 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	>3000000(SN)		
IDU prevalence estimate (%)	Low	Mid	High
	1	1.30	1.70
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	4 456 087 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	44 500	58 000	76 000
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	39.47	51.72	67.42

Condoms: All documents reviewed

Buxton, J. Personal Communication: Response to "Canada - UN Reference Group - Final Data Check". Canada, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 24 Sep 2009.

Expert Advisory Committee to the Federal Health Minister Canada (2008). Vancouver's INSITE Service and Other Supervised Injection Sites: What Has Been Learned from Research? Final Report of the Expert Advisory Committee on Supervised Injection Site Research. Ottawa, Health Canada.

Hogg, R., S. Strathdee, et al. (2005). "HIV Prevalence among Aboriginal British Columbians." Harm Reduction Journal 2(1): 26.

Ogborne, A., V. Carver, et al. (2005). Harm reduction and drug use: an international comparative study of contextual factors influencing the development and implementation of relevant policies and programs, Canadian Centre for Substance Abuse (CCSA).

Strike, C., Leonard, L., Millson, M, Anstice, S, Berkeley, N, & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.